APA (7th ed.) Citation

Marković, S., Kralj, Đ., Svorcan, P., Knežević Ivanovski, T., Odanović, O., Obradović, S., . . . Vučićević, K. M. (2024). Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics. Pharmaceutics, 16(12), 1629. https://doi.org/10.3390/pharmaceutics16121629

Chicago Style (17th ed.) Citation

Marković, Srđan, et al. "Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics." Pharmaceutics 16, no. 12 (2024): 1629. https://doi.org/10.3390/pharmaceutics16121629.

MLA (9th ed.) Citation

Marković, Srđan, et al. "Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics." Pharmaceutics, vol. 16, no. 12, 2024, p. 1629, https://doi.org/10.3390/pharmaceutics16121629.